Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Status:
Recruiting
Trial end date:
2027-08-01
Target enrollment:
Participant gender:
Summary
The safety, tolerability, and antileukemic response of ziftomenib in combination with
standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will
be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.